ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor–ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis—an observational study

BACKGROUND: Previous studies showed that the combination of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector and potentiator, lumacaftor–ivacaftor (LUMA–IVA) provides meaningful clinical benefits in patients with cystic fibrosis who are homozygous for the Phe508del CFTR mutation....

Descripción completa

Detalles Bibliográficos
Autores principales: Arooj, Parniya, Morrissy, David V, McCarthy, Yvonne, Vagg, Tamara, McCarthy, Mairead, Fleming, Claire, Daly, Mary, Eustace, Joseph A, Murphy, Desmond M, Plant, B J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Cystic Fibrosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163494/
https://www.ncbi.nlm.nih.gov/pubmed/37130650
http://dx.doi.org/10.1136/bmjresp-2022-001590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163494/
https://www.ncbi.nlm.nih.gov/pubmed/37130650
http://dx.doi.org/10.1136/bmjresp-2022-001590

Ejemplares similares